What Makes this GLP 1 Weight Loss Medication Different?
Overweight and obesity affect billions of people worldwide and increases the risk of serious health problems like heart disease, high blood pressure, and diabetes. While effective treatments exist, many of the newer options require injections, which can make them harder for some people to start or stick with.
A new medication called Orforglipron (Foundayo ™) changes how GLP 1 drugs are administered. It is a once-daily pill designed to support weight loss without injections or strict timing around meals. Researchers studied how well it works and how safe it is for adults with obesity.
How the Study Was Designed
This was a large, well-controlled study with more than 3,100 adults from multiple countries. All participants had obesity but did not have diabetes.
Participants were randomly assigned to receive one of three doses of Orforglipron (6 mg, 12 mg, or 36 mg) or a placebo. Everyone also received guidance on healthy eating and physical activity. The study lasted 72 weeks, which allowed researchers to evaluate long-term results.
What Kind of Weight Loss Did People See?
The results showed clear weight loss with Orforglipron, especially at higher doses. After 72 weeks:
- 6 mg: about 7.5% body weight loss
- 12 mg: about 8.4% loss
- 36 mg: about 11.2% loss
- Placebo: about 2.1% loss
Higher doses led to stronger results. Many participants also reached important milestones. For example, more than half of people on the highest dose lost at least 10% of their body weight, and a meaningful portion lost 15% to 20% or more.
Even a 10% weight loss is considered clinically important and can lead to real improvements in overall health.
Improvements in Overall Health
The benefits went beyond weight loss. People taking Orforglipron also showed improvements in several key health markers tied to heart and metabolic health.
These included:
- Smaller waist size
- Lower blood pressure
- Improved cholesterol levels
- Lower triglycerides
In addition, many people with prediabetes returned to normal blood sugar levels by the end of the study.
Researchers also looked at body composition in a smaller group. Most of the weight loss came from fat, especially harmful fat around internal organs, while a smaller portion came from lean mass. This pattern is expected with effective weight-loss treatments.
Side Effects and Safety
Like similar medications, Orforglipron mainly caused digestive side effects. The most common ones were:
- Nausea
- Diarrhea
- Constipation
- Vomiting
These were usually mild to moderate and often happened during dose increases. Some people stopped taking the medication because of side effects, but this was still a relatively small percentage.
Serious side effects were uncommon and occurred at similar rates across all groups. There were a few rare events, including cases of pancreatitis, but no major safety concerns stood out. Overall, the safety profile was similar to other medications in this class.
Why This Study Is Important
This research highlights a key shift: effective weight-loss treatment may not require injections. A daily pill that can be taken anytime during the day could make treatment easier and more accessible for many people.
Some potential advantages include:
- No injections required
- Simple once-daily dosing
- No strict food or timing rules
- Easier storage and distribution
While the weight loss seen here is slightly lower than some injectable options, the convenience could make a meaningful difference in real-world use. There are still limitations, including the lack of direct comparison with other treatments and the need for longer-term data.
The Bottom Line
Orforglipron (Foundayo ™) is a promising new oral treatment for obesity. It led to meaningful weight loss and improved several important health markers in a large clinical trial.
For people who prefer not to use injections, this medication could offer a simpler and more accessible option for managing weight and improving overall health.
Source
Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774
